Erschienen in:
22.12.2017 | Original Paper
Outcome of “treat and monitor” regimen of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion
verfasst von:
Francesco Pichi, Ahmed Mohammed Elbarky, Tarek Roshdy Elhamaky
Erschienen in:
International Ophthalmology
|
Ausgabe 1/2019
Einloggen, um Zugang zu erhalten
Abstract
Purpose
To compare the efficacy of a modified PRN treatment regimen (“treat and monitor”) of aflibercept and ranibizumab in macular edema secondary to non-ischemic branch retinal vein occlusion.
Methods
Seventy eyes of 70 patients with treatment naïve branch retinal vein occlusion were enrolled. All patients underwent a comprehensive ophthalmic examination, spectral-domain optical coherence tomography, and fluorescein angiography. Patients were randomized 1:1 to receive intravitreal aflibercept (34 eyes) and ranibizumab (36 eyes) with a “treat and monitor” treatment regimen with monthly follow-up for 12 months. Primary outcome measures included mean change in best corrected visual acuity (BCVA) and central foveal thickness (CFT) at month 12 compared to baseline.
Results
At 12 months follow-up, the mean BCVA improved from 0.58 ± 0.13 to 0.20 ± 0.15 logMAR (P = 0.0003) in the aflibercept group (mean injections 2.6 ± 1.51) and from 0.52 ± 0.11 to 0.21 ± 0.1 logMAR (P = 0.0002) in the ranibizumab group (mean injections 2.8 ± 1.78). No statistical difference between the two groups in terms of the visual acuity gains in eyes with macular edema secondary to non-ischemic BRVO treated with either aflibercept or ranibizumab was observed. Mean CFT reduced from 498 ± 46 to 204 ± 23 µm (P < 0.0001) in the aflibercept group and from 488 ± 31 to 212 ± 29 µm (P < 0.0001) in the ranibizumab group.
Conclusion
“Treat and monitor” regimen is a real-life effective strategy in improving visual acuity after macular edema from branch vein occlusion and in reducing the number of injections.